Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Propranolol for the Treatment of Kaposi Sarcoma in Children and Adults
NCT05797662Phase 2
Key facts
- Status
- Recruiting
- Start
- Aug 2026
- Primary completion
- Sep 2028
- Countries
- 5
- Sponsor
- AIDS Malignancy Consortium
- Modality
- Small Molecules
- Drugs
- propranolol
- Conditions
- Kaposi sarcoma (KS)
01
Overview
Phase 2, open-label, single-arm trial of propranolol in Kaposi sarcoma (KS), sponsored by AIDS Malignancy Consortium. Primary endpoint: Objective Response Rate at 1 year. Started Aug 2026; status: recruiting.
02
Design
1 arm- Study design
- Non-randomizedOpen-labelSingle group
Propranolol
Propranolol Twice Daily (BID) x 12 weeks. Dosage: For ages <= 12 years: 3mg/kg/day divided BID; for ages > 12 years, 120 mg BID.
03
Who it enrols
Pediatric and adult patients with biopsy-proven, measurable Kaposi Sarcoma, adequate organ function, and no history of asthma, diabetes, or significant cardiovascular disease.
04
Endpoints
Primary
Objective Response Rate
Secondary
Number of dose-limiting toxicities
Number of treatment-emergent adverse events
Complete and Partial Response rates
Time to recurrence
Time to progression
Beyond the preview
Go deeper on NCT05797662.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05797662.